Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What is the impact of polypharmacy in patients with Crohn's disease?

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 448–449 (2005)Cite this article

boxed-textCross RK et al. (2005) Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 21: 1211–1216

Patients with Crohn's disease should be evaluated regularly for appropriateness and completeness of treatment, with the aim of limiting the number of medications used

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Binder V et al. (1985) Prognosis in Crohn's disease—based on results from a regional patient group from the county of Copenhagen. Gut 26: 146–150

    Article  CAS  Google Scholar 

  2. Rutgeerts P et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402–413

    Article  CAS  Google Scholar 

  3. Hommes DW et al. (2003) Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how, and when? Curr Opin Gastroenterol 19: 350–357

    Article  CAS  Google Scholar 

  4. Korzenik JR et al. (2005) Sargramostim for active Crohn's disease. N Engl J Med 352: 2193–2201

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chief of the Division of Gastroenterology and Hepatology at Lausanne University Medical Center and Professor of Medicine at the University of Lausanne, Lausanne, Switzerland

    Pierre Michetti

Authors
  1. Pierre Michetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michetti, P. What is the impact of polypharmacy in patients with Crohn's disease?. Nat Rev Gastroenterol Hepatol 2, 448–449 (2005). https://doi.org/10.1038/ncpgasthep0294

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0294

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing